Clinical trial Recruiting at 1 site Observational Ages 18 and up

Understanding post‑cardiac arrest brain injury through spinal fluid molecular analysis

Official title: Identification of Novel Molecular Pathophysiological Mechanisms of Secondary Brain Injury in Post-cardiac Arrest Syndrome Patients Using Cerebrospinal Fluid Multi-omics Analysis

Run by Chungnam National University Hospital · NCT07481396 · Data updated 2026-11-12

This project will test whether detailed molecular analysis of spinal fluid from people who had a cardiac arrest can reveal targets for new treatments.

Quick facts

Study typeObservational
Ages18 Years and up
SexAll
Enrollment60 (estimated)
SponsorChungnam National University Hospital
Academic / other
Locations1 site (Daejeon, Jung-gu)
StatusRecruiting
StartedDecember 1, 2025
Main results expectedNovember 30, 2027
Study endsFebruary 28, 2028
Registry record updatedMarch 18, 2026
Trial IDNCT07481396 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are patients receiving post‑resuscitation care after out‑of‑hospital cardiac arrest who can safely undergo lumbar puncture without bleeding, infection, or other contraindications.

Probably not a fit

Patients with cerebral edema on immediate post‑resuscitation CT, those on ECMO, or those with contraindications to lumbar puncture are unlikely to participate or benefit from the CSF‑based findings.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The protocol collects cerebrospinal fluid (CSF) from patients receiving post‑resuscitation care after out‑of‑hospital cardiac arrest and performs multi‑omics profiling across the genome, transcriptome, proteome, and metabolome. Identified molecular pathways will be compared with drug databases and used in computational modeling to nominate existing compounds or design new candidates. Promising candidates will be synthesized and prioritized to provide rationale for future preclinical experiments in cardiac arrest animal models. Patients with contraindications to lumbar puncture, evidence of cerebral edema, or those treated with ECMO are excluded from sampling.

Why it matters

Potential benefit: If successful, the work could identify molecular targets in CSF that lead to new therapies to reduce secondary brain injury after cardiac arrest.

How similar studies have gone: Related proteomic and metabolomic CSF studies in brain injury have found candidate biomarkers, but multi‑omics approaches linking findings to drug candidates remain largely exploratory and not yet translated to therapies.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Patients receiving post-resuscitation care after out-of-hospital cardiac arrest for secondary brain injury treatment.
* Patients without contraindications for lumbar puncture catheter insertion for cerebrospinal fluid (CSF) collection. This includes the absence of:
* Uncontrolled diabetes.Coagulation disorders.
* Thrombocytopenia (platelet count $\< 100,000).
* A history of cirrhosis diagnosis.
* Current receipt of low molecular weight heparin.
* Current use of platelet inhibitors.
* A history of posterior spinal fusion that may interfere with catheter insertion.
* Local skin infection or rash at the puncture site.
* Signs of systemic infection or sepsis.
* A history of lumbar puncture within the past 6 hours.

Exclusion Criteria:

* Cerebral Edema: Patients with evidence of cerebral edema on a brain computed tomography (CT) scan performed immediately after spontaneous circulation recovery.
* Patients who underwent extracorporeal membrane oxygenation (ECMO).
* Patients who could not maintain integrated therapy for more than 24 hours after cardiac arrest.
* Patients with a history of acute or chronic brain disease.

Where it's running

  • Chungnam National University Hospital
    Daejeon, Jung-gu, South Korea
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.